GERRESHEIMER should benefit from the launch of Wegovy in Japan. GLP1 products offer a sales opportunity of several hundred million euros!
Reading Time: 1 minute
Novo Nordisk launches Wegovy in Japan on 02-22-2024. GLP-1 products will boom in the next few years! Gerresheimer supplies all relevant GLP-1 manufacturers with drug delivery systems. The share now has recovery potential! Novo Nordisk announced today that it plans to launch the weight loss drug Wegovy in Japan on February 22, 2024. This would be the sixth country where the anti-obesity product would be available, despite bottlenecks due to high demand. Gerresheimer is a beneficiary of internationalization, as the Group has all major GLP-1...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
